Slide 1: Investor presentation
Investor presentation June 2024
Slide 2: Disclaimer and safe harbor
Disclaimer and safe harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements
Slide 3: Our vision
Our vision To be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines Oncology Rare Disease Neuroscience
Slide 4: Focus. Together. For patients
Our strategy Bringing full potential of our Building innovative medicines a high-value, to patients sustainable pipeline Focus. Together. For patients Delivering & society efficiencies to enable Boosting investments & a culture of support growth collaboration, excellence & impact on society 4
Slide 5: Ipsen's nine major medicines
Ipsen’s nine major medicines Motor muscular disorders Neuroscience Medical aesthetics Oncology Metastatic prostate cancer Growth platforms Oncology RCC: monotherapy & in combination Oncology Metastatic pancreatic cancer Oncology Neuroendocrine tumors Rare Disease Primary biliary cholangitis Rare Dis
Slide 6: Ipsen's total sales: FY 2023
Ipsen’s total sales: FY 2023 Oncology Neuroscience Somatuline Decapeptyl Rare Cabometyx Disease Onivyde Tazverik Other Oncology Bylvay Sohonos NutropinAq Increlex Dysport Other Neuroscience 6
Slide 7: A strong platform for growth
A strong platform for growth Growth platforms & new medicines continue to drive momentum External innovation New Total sales medicines Growth platforms Somatuline Today Time 7
Slide 8: More balanced split of sales by three therapy areas
More balanced split of sales by three therapy areas Oncology Rare Disease Neuroscience 75% 4% 21% of total of total of total sales1 sales1 sales1 Growth driven by Multiple launches: Sustained growth Onivyde 1L mPDAC & Bylvay, Iqirvo & Sohonos of Dysport in Tx & Ax Cabometyx Future growth: Future gro
Slide 9: Global leader with growth across all regions
Global leader with growth across all regions North America Europe Rest of World 33% 40% 27% of total sales1 of total sales1 of total sales1 Leveraging platform through Sustained growth driven by Multiple opportunities in multiple launches Dysport & Cabometyx Asia-Pacific & Latin America Future growt
Slide 10: Increasingly diversified portfolio
Increasingly diversified portfolio Seven medicines: potential sales ≥€500m 2027+ Four medicines: sales ≥€500m 2023 One medicine: sales ≥€500m 2020 10
Slide 11: Our growth journey
Our growth journey Next phase of transformation built on strong foundations 2028+ Lasting momentum 2024-2027 Balanced & diversified Dynamic growth portfolio across three therapy areas 2020-2023 Several launches Sustained growth, Setting foundations supported by pipeline & Further pipeline expansion
Slide 12: Launching four new medicines or new indications
Launching four new medicines or new indications Building Rare Disease franchise & strengthening Oncology 1L mPDAC Launched in Q1 2024: U.S. U.S. launch underway ALGS EMA: H2 2024 US approval: June 2024 2L PBC EMA decision: H2 2024 FOP Launched in 2023: U.S. & Australia 1L: first line; mPDAC: metasta
Slide 13: Onivyde: significant potential in 1L mPDAC
Onivyde: significant potential in 1L mPDAC U.S. Phase III NAPOLI-3 trial: annual incidence of patients receiving treatment positive results Patients not receiving Differentiated clinical profile any active treatment / & strong data deceased patients 1L ~35k patients1 PDUFA date: 13 February 2L 2024,
Slide 14: Onivyde: increasing share in 1L mPDAC
Onivyde: increasing share in 1L mPDAC U.S. 1L mPDAC market % of active patients1 Potential to become new SoC in 1L mPDAC by gaining market 100% share in all segments Onivyde 2% irinotecan-based 43% Building on our footprint in pancreatic cancer gem-based 41% Leveraging strong commercial Other² & med
Slide 15: An encouraging early start in 1L mPDAC
An encouraging early start in 1L mPDAC Significant Potential potential, to become new standard of with high unmet care medical need U.S. FDA approval: 13 February Patients SoC Orphan Exclusivity in 1L to 2031 Positive uplift in post-launch ` demand “The approval of this Onivyde regimen is an importa
Slide 16: Iqirvo: opportunity to expand global 2L PBC market
Iqirvo: opportunity to expand global 2L PBC market U.S. example: 2L PBC patient flow: Underdeveloped global 2L PBC market number of U.S. patients Significant unmet medical need – Dissatisfaction with current treatment options – Uncontrolled disease Limited share (20-40%) of eligible patients Patient
Slide 17: A high-value, sustainable pipeline
A high-value, sustainable pipeline Phase I Phase II Phase III Registration IPN60210 FIDRISERTIB CABOMETYX + ONIVYDE + 5-FU/LV + R/R multiple myeloma ATEZOLIZUMAB OXALIPLATIN1 & R/R DLBCL FOP 2L mCRPC 1L mPDAC IPN60260 IQIRVO TAZVERIK + R2 ODEVIXIBAT2 Viral cholestatic disease PSC 2L FL Alagille synd
Slide 18: Near to mid-term outlook
Data Regulatory Near to mid-term outlook readout decision Key milestones Medicine 2024 2025 2026 Onivyde 1L mPDAC, FDA Iqirvo 2L PBC, FDA Odevixibat ALGS, E.U. Cabometyx mCRPC, Phase III Fidrisertib FOP, Phase II Bylvay BA, Phase III Dysport Migraine, Phase III Tazverik 2L FL, Phase III1 1L: first l
Slide 19: Clear strategy to continue external innovation
Clear strategy to continue external innovation Oncology Rare Disease Neuroscience €300-800m peak sales Solid tumors & High unmet needs Rare neurological hematology in underserved rare disorders diseases Balance early – niche tumors & late-stage – biomarker segments assets Preference Smaller patient
Slide 20: Generation Ipsen: sustainability-performance update
Generation Ipsen: sustainability-performance update Pillars KPIs 2023 performance Science-based GHG-emission reductions1 vs 2019 baseline by 2030 Environment Scope 1&2: -50% Scope 1&2: -36% Scope 3: -20% Scope 3: -29% Reduce time to make non-FDA/EMA Patients regulatory submissions by 25% First data
Slide 21: Multiple growth opportunities by medicine
Multiple growth opportunities by medicine Global peak sales / direction Peak sales >€700m1 Peak sales >€500m Oncology Peak sales >€500m2 Mid-single digit growth3 Peak sales >€700m4 Rare Disease Peak sales >€500m5 Peak sales >€100m Neuroscience High-single digit growth3 1 Excluding additional potenti
Slide 22: 2027 mid-term outlook
2027 mid-term outlook Excluding potential additional late-stage1 external-innovation opportunities TOTAL-SALES: CORE OPERATING CAGR 2023-2027 MARGIN 2027 ≥+7% ≥32% of total sales at constant exchange rates ` Launches of new medicines & Limited decline in additional indications gross-margin Growth pl
Slide 23: Drivers of 2027 core operating margin
Drivers of 2027 core operating margin Gross margin R&D SG&A ≥85% ≥20% ≤35% Manufacturing gains Investment to support Leverage commercial to lower unit costs internal & external infrastructure & targeted innovation pipeline investment for launches Unfavorable sales mix Optimization of footprint Syner
Slide 24: Capital-allocation framework
Capital-allocation framework Cumulative firepower of up Increased free Limited to €5bn by 2027, based on net cash-flow evolution debt1 at 2.0x EBITDA generation of dividend Priority for capital allocation Multiple transactions from licensing & acquisitions External Innovation Financial discipline ba
Slide 25: Conclusion
Conclusion Successfully executing on a consistent strategy to continue our growth journey Advancing the Excellence in 2027 pipeline execution mid-term outlook1 Focused platform across Commercial & medical Total-sales growth: three therapy areas execution underpinning CAGR, 2023-2027 attractive oppor
Slide 26: Investor presentation
Investor presentation June 2024
Slide 27: LANT: therapeutic & aesthetic evaluation
LANT: therapeutic & aesthetic evaluation LANTIMA (n=209) & LANTIC (n=191): Phase II ongoing global, double-blind, multi-center trials Evaluating safety & efficacy – LANTIMA: adult upper-limb spasticity – LANTIC: severe upper-facial lines Dose escalation & dose-finding trial Recombinant toxin, engine
Slide 28: Oncology
Oncology Key ongoing clinical-trial highlights PRIMARY TRIAL POPULATION PATIENTS DESIGN STATUS ENDPOINT(S) Second novel hormonal Cabometyx therapy (abiraterone & PFS endpoint met CONTACT-02 2L mCRPC 575 prednisone or enzalutamide) PFS, OS Phase III or Awaiting OS data NCT04446117 Cabometyx + atezoli
Slide 29: Oncology
Oncology Key ongoing clinical-trial highlights PRIMARY TRIAL POPULATION PATIENTS DESIGN STATUS ENDPOINT(S) IPN60210 R/R multiple Treatment-emergent adverse Phase I/Ib myeloma & 96 IPN60210 Recruiting1 events, dosing & ORR NCT05121103 R/R DLBCL IPN01194 Dose escalation, treatment Solid tumors Phase I
Slide 30: Rare Disease
Rare Disease Key ongoing clinical-trial highlights TRIAL POPULATION PATIENTS DESIGN PRIMARY ENDPOINT STATUS Regulatory approval: U.S.: Iqirvo Response to treatment Placebo June 2024 ELATIVE defined as ALP < 1.67 x ULN 2L PBC 161 or Phase III and total bilirubin ≤ ULN and Iqirvo Regulatory decision:
Slide 31: Rare Disease
Rare Disease Key ongoing clinical-trial highlights PRIMARY TRIAL POPULATION PATIENTS DESIGN STATUS ENDPOINT(S) Bylvay Placebo ASSERT Change from baseline in Regulatory decision: Alagille syndrome 52 or Phase III scratching score E.U.: H2 2024 odevixibat NCT04674761 10mg ritivixibat tablet QD for Rit
Slide 32: Neuroscience
Neuroscience Key ongoing clinical-trial highlights PRIMARY TRIAL POPULATION PATIENTS DESIGN STATUS ENDPOINT IPN10200 Ax Moderate to Dose escalation & LANTIC severe upper facial 727 dose-finding versus Safety Active, not recruiting1 Phase II NCT04821089 lines Dysport or placebo IPN10200 Tx Adult pati
Slide 33: Investor Relations
Investor Relations Craig Marks Nicolas Bogler Vice President, Investor Relations Investor Relations Senior Manager +44 7564 349 193 +33 6 52 19 98 92 craig.marks@ipsen.com nicolas.bogler@ipsen.com 33
Slide 34: Thank you
Thank you Follow us: www.ipsen.com